Tag: FOR

Luxembourg, August 6, 2025 – In line with the press release published on June 13, 2025, the Board of Directors of Millicom International Cellular S.A. (“Millicom”) approved the interim dividend of $2.50 per share, to be paid in two equal installments of $1.25 per share on October 15, 2025 and April 15, 2026. Other important dates and information relating to the Interim Dividend are as follows:

SPOKANE, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.49 per share on the company’s common stock. The common stock dividend is payable September 15, 2025, to shareholders of record at the close of business on August 19, 2025.

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

BRADENTON, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (“FWRG” or the “Company”) (NASDAQ: FWRG), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the launch of an underwritten secondary offering (the “Offering”) by certain funds managed by Advent International, L.P. (the “Selling Stockholders”) of 5,000,000 shares of the Company’s common stock (“Common Stock”).

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.